|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NR3C2 |
Gene summary for NR3C2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NR3C2 | Gene ID | 4306 |
| Gene name | nuclear receptor subfamily 3 group C member 2 | |
| Gene Alias | MCR | |
| Cytomap | 4q31.23 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B0ZBF6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4306 | NR3C2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.33e-50 | -9.03e-01 | 0.0155 |
| 4306 | NR3C2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.50e-06 | -8.57e-01 | 0.0216 |
| 4306 | NR3C2 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.33e-25 | 1.00e+00 | -0.1954 |
| 4306 | NR3C2 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.42e-13 | 9.07e-01 | -0.2602 |
| 4306 | NR3C2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 4.17e-10 | 7.07e-01 | -0.2196 |
| 4306 | NR3C2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.86e-02 | 3.26e-01 | -0.1526 |
| 4306 | NR3C2 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.17e-10 | 6.02e-01 | -0.1464 |
| 4306 | NR3C2 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.49e-11 | 6.02e-01 | -0.1001 |
| 4306 | NR3C2 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.59e-15 | -6.77e-01 | 0.096 |
| 4306 | NR3C2 | HTA11_9408_2000001011 | Human | Colorectum | AD | 4.39e-05 | -5.90e-01 | 0.0451 |
| 4306 | NR3C2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.59e-09 | -8.33e-01 | 0.0528 |
| 4306 | NR3C2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.50e-08 | -5.34e-01 | 0.0338 |
| 4306 | NR3C2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.59e-31 | -7.81e-01 | 0.0674 |
| 4306 | NR3C2 | HTA11_7469_2000001011 | Human | Colorectum | AD | 5.39e-03 | -6.79e-01 | -0.0124 |
| 4306 | NR3C2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 5.35e-32 | -9.89e-01 | 0.0588 |
| 4306 | NR3C2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.70e-79 | -1.20e+00 | 0.294 |
| 4306 | NR3C2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.83e-71 | -1.18e+00 | 0.3859 |
| 4306 | NR3C2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 4.69e-36 | -1.30e+00 | 0.2585 |
| 4306 | NR3C2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.24e-111 | -1.59e+00 | 0.3005 |
| 4306 | NR3C2 | F007 | Human | Colorectum | FAP | 9.75e-04 | -3.49e-01 | 0.1176 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0071383 | Colorectum | AD | cellular response to steroid hormone stimulus | 73/3918 | 204/18723 | 6.31e-07 | 2.24e-05 | 73 |
| GO:0030522 | Colorectum | AD | intracellular receptor signaling pathway | 87/3918 | 265/18723 | 3.69e-06 | 1.03e-04 | 87 |
| GO:0043401 | Colorectum | AD | steroid hormone mediated signaling pathway | 51/3918 | 136/18723 | 6.52e-06 | 1.63e-04 | 51 |
| GO:0048545 | Colorectum | AD | response to steroid hormone | 104/3918 | 339/18723 | 1.33e-05 | 2.90e-04 | 104 |
| GO:0009755 | Colorectum | AD | hormone-mediated signaling pathway | 64/3918 | 190/18723 | 2.78e-05 | 5.24e-04 | 64 |
| GO:0030518 | Colorectum | AD | intracellular steroid hormone receptor signaling pathway | 43/3918 | 116/18723 | 4.61e-05 | 7.97e-04 | 43 |
| GO:00713831 | Colorectum | SER | cellular response to steroid hormone stimulus | 55/2897 | 204/18723 | 1.66e-05 | 5.05e-04 | 55 |
| GO:00485451 | Colorectum | SER | response to steroid hormone | 80/2897 | 339/18723 | 5.15e-05 | 1.25e-03 | 80 |
| GO:00434011 | Colorectum | SER | steroid hormone mediated signaling pathway | 38/2897 | 136/18723 | 1.42e-04 | 2.82e-03 | 38 |
| GO:00097551 | Colorectum | SER | hormone-mediated signaling pathway | 49/2897 | 190/18723 | 1.54e-04 | 3.00e-03 | 49 |
| GO:00305221 | Colorectum | SER | intracellular receptor signaling pathway | 63/2897 | 265/18723 | 2.47e-04 | 4.20e-03 | 63 |
| GO:00305181 | Colorectum | SER | intracellular steroid hormone receptor signaling pathway | 31/2897 | 116/18723 | 1.25e-03 | 1.41e-02 | 31 |
| GO:00713832 | Colorectum | MSS | cellular response to steroid hormone stimulus | 72/3467 | 204/18723 | 8.87e-09 | 5.43e-07 | 72 |
| GO:00434012 | Colorectum | MSS | steroid hormone mediated signaling pathway | 51/3467 | 136/18723 | 1.43e-07 | 6.67e-06 | 51 |
| GO:00305222 | Colorectum | MSS | intracellular receptor signaling pathway | 84/3467 | 265/18723 | 1.47e-07 | 6.79e-06 | 84 |
| GO:00485452 | Colorectum | MSS | response to steroid hormone | 101/3467 | 339/18723 | 2.60e-07 | 1.10e-05 | 101 |
| GO:00305182 | Colorectum | MSS | intracellular steroid hormone receptor signaling pathway | 44/3467 | 116/18723 | 6.95e-07 | 2.49e-05 | 44 |
| GO:00097552 | Colorectum | MSS | hormone-mediated signaling pathway | 63/3467 | 190/18723 | 9.26e-07 | 3.23e-05 | 63 |
| GO:00713833 | Colorectum | FAP | cellular response to steroid hormone stimulus | 59/2622 | 204/18723 | 2.12e-08 | 2.06e-06 | 59 |
| GO:00485454 | Colorectum | FAP | response to steroid hormone | 81/2622 | 339/18723 | 6.22e-07 | 3.08e-05 | 81 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04960 | Colorectum | FAP | Aldosterone-regulated sodium reabsorption | 13/1404 | 37/8465 | 4.79e-03 | 1.91e-02 | 1.16e-02 | 13 |
| hsa049601 | Colorectum | FAP | Aldosterone-regulated sodium reabsorption | 13/1404 | 37/8465 | 4.79e-03 | 1.91e-02 | 1.16e-02 | 13 |
| hsa049602 | Colorectum | CRC | Aldosterone-regulated sodium reabsorption | 12/1091 | 37/8465 | 1.66e-03 | 1.20e-02 | 8.16e-03 | 12 |
| hsa049603 | Colorectum | CRC | Aldosterone-regulated sodium reabsorption | 12/1091 | 37/8465 | 1.66e-03 | 1.20e-02 | 8.16e-03 | 12 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| NR3C2 | MAST | Colorectum | MSS | SLC4A4,SLC26A2,SATB2, etc. | 4.05e-02 |  |
| NR3C2 | CD8TEXP | Endometrium | ADJ | ANK3,RASGRF2,IL7R, etc. | 2.64e-01 |  |
| NR3C2 | TH17 | Endometrium | ADJ | ANK3,RASGRF2,IL7R, etc. | 7.94e-02 | |
| NR3C2 | TFH | Endometrium | AEH | ANK3,RASGRF2,IL7R, etc. | 2.17e-01 |  |
| NR3C2 | CD8TEXP | Endometrium | AEH | ANK3,RASGRF2,IL7R, etc. | 1.18e-01 | |
| NR3C2 | TH17 | Endometrium | AEH | ANK3,RASGRF2,IL7R, etc. | 1.05e-01 | |
| NR3C2 | TH17 | Endometrium | EEC | ANK3,RASGRF2,IL7R, etc. | 6.22e-02 |  |
| NR3C2 | CD8TEXP | Endometrium | EEC | ANK3,RASGRF2,IL7R, etc. | 1.35e-01 | |
| NR3C2 | CD4TN | Endometrium | Healthy | ANK3,RASGRF2,IL7R, etc. | 1.94e-01 |  |
| NR3C2 | CD8TEXP | Endometrium | Healthy | ANK3,RASGRF2,IL7R, etc. | 1.61e-01 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NR3C2 | SNV | Missense_Mutation | rs776434075 | c.1091N>T | p.Thr364Met | p.T364M | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.945) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| NR3C2 | SNV | Missense_Mutation | c.1220N>C | p.Ser407Thr | p.S407T | protein_coding | tolerated_low_confidence(0.35) | benign(0.145) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | CR | |||
| NR3C2 | SNV | Missense_Mutation | c.2870N>T | p.Pro957Leu | p.P957L | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD | ||
| NR3C2 | SNV | Missense_Mutation | c.1959G>T | p.Lys653Asn | p.K653N | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| NR3C2 | SNV | Missense_Mutation | novel | c.2113N>C | p.Glu705Gln | p.E705Q | protein_coding | tolerated(0.34) | benign(0.09) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NR3C2 | SNV | Missense_Mutation | rs770059383 | c.53N>A | p.Arg18Gln | p.R18Q | protein_coding | tolerated_low_confidence(0.14) | benign(0) | TCGA-AR-A2LN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD | |
| NR3C2 | SNV | Missense_Mutation | c.344C>T | p.Ala115Val | p.A115V | protein_coding | deleterious_low_confidence(0) | benign(0.21) | TCGA-BH-A0HB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | ||
| NR3C2 | SNV | Missense_Mutation | novel | c.834N>A | p.His278Gln | p.H278Q | protein_coding | tolerated_low_confidence(0.19) | possibly_damaging(0.579) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD | |
| NR3C2 | insertion | In_Frame_Ins | novel | c.2097_2098insGTGGCTCACGCCTGTAATCCCAGCACTTTG | p.Pro699_Pro700insValAlaHisAlaCysAsnProSerThrLeu | p.P699_P700insVAHACNPSTL | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | |||
| NR3C2 | insertion | Frame_Shift_Ins | novel | c.2218_2219insG | p.Met740SerfsTer4 | p.M740Sfs*4 | protein_coding | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | agonist | CHEMBL1200592 | DESOXYCORTICOSTERONE PIVALATE | |
| 4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | PMID27551786-Compound-106 | |||
| 4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | agonist | 135651469 | ||
| 4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | antagonist | 135651551 | PROGESTERONE | |
| 4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | antagonist | 135650760 | ONAPRISTONE | |
| 4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | PROGESTERONE | PROGESTERONE | ||
| 4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | FLUDROCORTISONE | FLUDROCORTISONE | ||
| 4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | KBP-5074 | |||
| 4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | PMID27551786-Compound-II | |||
| 4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | EPLERENONE | EPLERENONE |
| Page: 1 2 3 4 5 6 7 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |